Polymer-Linked cGMP Multimers for Potent PKG and CNGC Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cGMP analogues, such as Rp-8-Br-cGMPS and Rp-8-Br-PET-cGMPS, are not optimal for inhibiting the cGMP-dependent protein kinase (PKG) and cyclic nucleotide-gated ion channels (CNGC), require high doses for efficacy, and have limited membrane permeability, hindering their application in treating retinal dystrophies and other cGMP-related diseases.
Innovation Solution
Development of equatorially modified polymer linked multimeric cGMP (PLM) analogues with improved synthetic methods, allowing for effective inhibition of multiple cGMP targets, including PKG and CNGC, using regioselective strategies and diverse spacer lengths to enhance inhibitory potency.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If equatorially modified cGMP analogues (Rp-cGMPS, Rp-8-Cl-cGMPS) are used to inhibit PKG, then inhibitory effect is achieved, but membrane permeability remains insufficient
Solution Approach 1:
The patent modifies the chemical parameters of cGMP analogues by introducing equatorial substitutions (sulfur atoms at the 3′ position) and creating multimeric structures with polyethylene glycol linkers. These parameter changes improve membrane permeability while maintaining inhibitory activity against PKG and CNGC, resolving the contradiction between reliability of inhibition and ease of cellular uptake.
Solution Approach 2:
The invention creates composite molecular structures by linking multiple cGMP units through polyethylene glycol spacers. These composite multimeric analogues combine the inhibitory properties of individual cGMP units with improved pharmacokinetic properties, achieving both reliable inhibition and sufficient membrane permeability.
2Reliability
If higher doses of current cGMP analogues are administered, then inhibitory efficacy is improved, but specificity decreases and side effects increase
Solution Approach 1:
The patent changes the structural parameters of cGMP analogues by creating multimeric structures with specific spacer lengths and equatorial modifications. These parameter changes enhance binding affinity and specificity for PKG and CNGC targets, allowing effective inhibition at lower doses without the loss of specificity and side effects associated with high-dose monomeric analogues.
Solution Approach 2:
The invention introduces specific local modifications at the equatorial position of the cGMP molecule (sulfur substitution at 3′ position) and uses targeted spacer designs in multimeric structures. These local quality changes improve target recognition and binding specificity, enabling effective inhibition without requiring high doses that would cause off-target effects.
3Device complexity
If monomeric cGMP analogues are used, then simplicity is maintained, but inhibitory potency is insufficient requiring micromolar to millimolar concentrations
Solution Approach 1:
The patent merges multiple cGMP units into multimeric structures connected by polyethylene glycol linkers. This combining of multiple active units in a single molecule dramatically enhances inhibitory potency, allowing effective target inhibition at nanomolar concentrations rather than the micromolar to millimolar concentrations required by monomeric analogues.
Solution Approach 2:
The invention creates composite multimeric molecules that combine multiple cGMP pharmacophores with flexible polyethylene glycol spacers. These composite structures achieve high inhibitory potency through cooperative binding while maintaining solubility and appropriate pharmacokinetic properties, overcoming the limitations of simple monomeric structures.
Data Source
AI summary
Embodiments of the invention are directed to new equatorially modified polymer linked multimers of guanosine-3′, 5′-cyclic monophosphate (cGMP) analogues that inhibit the cGMP-signaling system. The invention is also directed to related monomeric compounds, which may serve as monomeric precursors of the multimers, and/or also show itself inhibitory activity and/or impact the inhibitory activity of the related multimers. The invention further relates to the use of such compounds as reagents for signal transduction research and as modulators of cyclic nucleotide-regulated binding proteins and isoenzymes thereof, and as ligands for affinity chromatography, for antibody production or for diagnostic applications, e.g., on chip surfaces.